Zacks Investment Research downgraded shares of Amedisys (NASDAQ:AMED) from a buy rating to a hold rating in a research note published on Friday, January 19th.
According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”
A number of other analysts also recently issued reports on the stock. BidaskClub downgraded shares of Amedisys from a sell rating to a strong sell rating in a report on Thursday, January 11th. Benchmark reiterated a hold rating on shares of Amedisys in a research report on Thursday, November 9th. Robert W. Baird reiterated a hold rating and set a $50.00 price target on shares of Amedisys in a research report on Wednesday, October 4th. Mizuho reiterated a buy rating and set a $65.00 price target (up previously from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. Finally, SunTrust Banks reiterated a buy rating and set a $70.00 price target on shares of Amedisys in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $60.64.
Amedisys (NASDAQ:AMED) traded up $1.02 during trading on Friday, reaching $56.05. 249,922 shares of the company were exchanged, compared to its average volume of 349,301. Amedisys has a fifty-two week low of $45.60 and a fifty-two week high of $65.91. The stock has a market cap of $1,878.40, a price-to-earnings ratio of 44.84, a price-to-earnings-growth ratio of 1.16 and a beta of 0.73. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33.
Institutional investors and hedge funds have recently made changes to their positions in the business. Riverhead Capital Management LLC lifted its holdings in shares of Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after acquiring an additional 831 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after acquiring an additional 44 shares during the last quarter. LS Investment Advisors LLC lifted its holdings in shares of Amedisys by 233.1% in the 4th quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock worth $188,000 after acquiring an additional 2,494 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in shares of Amedisys in the 3rd quarter worth about $205,000. Finally, Amalgamated Bank bought a new stake in shares of Amedisys in the 2nd quarter worth about $246,000. Institutional investors and hedge funds own 93.73% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Amedisys (NASDAQ:AMED) Downgraded by Zacks Investment Research” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/zacks-investment-research-downgrades-amedisys-amed-to-hold-4.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Get a free copy of the Zacks research report on Amedisys (AMED)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.